Pfizer Ventures led the immuno-oncology drug developer's latest round, which was spun out of Institut Paoli-Calmettes with the help of Satt Sud-Est and Inserm Transfert.

Azeria Therapeutics has picked up Syncona as an investor as it looks to bring its therapy for receptor-positive luminal breast cancer into the clinic.

MIT-founded regenerative polymer developer Tissium will put the capital into clinical-stage development and toward regulatory clearance in multiple markets.

OUP returned for PMV's series C round which the company will use to cement its portfolio of small molecule treatments targeting cancerous p53 mutations.

HawkEye 360 extended its series B round to at least $85m with a $15m contribution from family office Advance, which has also bought founding investor Allied Minds' stake.

Stanford-StartX Fund-backed smart mattress manufacturer Eight Sleep has increased its total funding to almost $65m following a $40m series C round led by Founders Fund.

University of Pennsylvania returned for a series B round that boosted its immunotherapy spinout's overall funding to $231m.

Shine Medical has increased its lifetime funding to around $283m as it prepares to launch medical isotope production plants leveraging fusion-based neutron generators invented at UW-Madison.

University of Maryland and Duke University-founded quantum computer developer IonQ has added $55m from investors including Osage University Partners and several corporates.

3SBio and Alexandria Venture Investments have both contributed to a $50m round raised by Verseau, which is developing immunotherapies based on MIT research.